|
|
Blood, 15 March 2008, Vol. 111, No. 6, pp. 3200-3210.
Prepublished online as a Blood First Edition Paper on January 9, 2008; DOI 10.1182/blood-2007-10-119099.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Pathway analysis of primary central nervous system lymphoma
Han W. Tun1,
David Personett2,
Karen A. Baskerville2,
David M. Menke3,
Kurt A. Jaeckle4,
Pamela Kreinest5,
Brandy Edenfield5,
Abba C. Zubair3,
Brian P. O'Neill6,
Weil R. Lai7,
Peter J. Park7, and
Michael McKinney2
Departments of1 Hematology and Oncology,
2 Molecular Pharmacology and Therapeutics,
3 Pathology,
4 Neurology, and
5 Cancer Biology, Mayo Clinic Jacksonville, FL;
6 Department of Neurology, Mayo Clinic Rochester, MN; and
7 Harvard-Partners Center for Genetics and Genomics, Boston, MA
Primary central nervous system (CNS) lymphoma (PCNSL) is a diffuse large B-cell lymphoma (DLBCL) confined to the CNS. A genome-wide gene expression comparison between PCNSL and non-CNS DLBCL was performed, the latter consisting of both nodal and extranodal DLBCL (nDLBCL and enDLBCL), to identify a "CNS signature." Pathway analysis with the program SigPathway revealed that PCNSL is characterized notably by significant differential expression of multiple extracellular matrix (ECM) and adhesion-related pathways. The most significantly up-regulated gene is the ECM-related osteopontin (SPP1). Expression at the protein level of ECM-related SPP1 and CHI3L1 in PCNSL cells was demonstrated by immunohistochemistry. The alterations in gene expression can be interpreted within several biologic contexts with implications for PCNSL, including CNS tropism (ECM and adhesion-related pathways, SPP1, DDR1), B-cell migration (CXCL13, SPP1), activated B-cell subtype (MUM1), lymphoproliferation (SPP1, TCL1A, CHI3L1), aggressive clinical behavior (SPP1, CHI3L1, MUM1), and aggressive metastatic cancer phenotype (SPP1, CHI3L1). The gene expression signature discovered in our study may represent a true "CNS signature" because we contrasted PCNSL with wide-spectrum non-CNS DLBCL on a genomic scale and performed an in-depth bioinformatic analysis.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Articles in Blood Online:
-
Differential gene expression in central nervous system lymphoma
- James L. Rubenstein, Arthur Shen, Tracy T. Batchelor, Cigall Kadoch, Patrick Treseler, and Marc A. Shuman
Blood 2009 113: 266-267.
[Full Text]
[PDF]
-
Differential gene expression of central nervous system lymphoma
- Han W. Tun and Michael McKinney
Blood 2009 113: 267-268.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
C. Kadoch, E. B. Dinca, R. Voicu, L. Chen, D. Nguyen, S. Parikh, J. Karrim, M. A. Shuman, C. A. Lowell, P. A. Treseler, et al.
Pathologic Correlates of Primary Central Nervous System Lymphoma Defined in an Orthotopic Xenograft Model
Clin. Cancer Res.,
March 15, 2009;
15(6):
1989 - 1997.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. S. Jaffe
The 2008 WHO classification of lymphomas: implications for clinical practice and translational research
Hematology,
January 1, 2009;
2009(1):
523 - 531.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Rubenstein, A. Shen, T. T. Batchelor, C. Kadoch, P. Treseler, and M. A. Shuman
Differential gene expression in central nervous system lymphoma
Blood,
January 1, 2009;
113(1):
266 - 267.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. W. Tun and M. McKinney
Differential gene expression of central nervous system lymphoma
Blood,
January 1, 2009;
113(1):
267 - 268.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Montesinos-Rongen, R. Siebert, and M. Deckert
Primary lymphoma of the central nervous system: just DLBCL or not?
Blood,
January 1, 2009;
113(1):
7 - 10.
[Full Text]
[PDF]
|
|
|
|
|
